IDM-4 Uses, Dosage, Side Effects and more
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely been discontinued by the manufacturer.
This monoclonal antibody-specific antigen selectively targets cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.
| Trade Name | IDM-4 |
| Generic | IDM-4 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in leukemia (lymphoid).
How IDM-4 works
The lipid promotes fusion of liposomes to cells. Specifically, IDM-4 targets tumor cells by coupling MAK cells with tumor antigens obtained from the patient.
Toxicity
Toxicity is reported to be low for various Monoclonal antibodies.
